Skip to content

Study on the mechanism that Ganlu Qingwen formula alleviates acute lung injury through the Nrf2-mediated ferroptosis pathway

Study on the mechanism that Ganlu Qingwen formula alleviates acute lung injury through the Nrf2-mediated ferroptosis pathway

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095256
Enrollment
Unknown
Registered
2025-01-03
Start date
2024-02-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

community-acquired pneumonia

Interventions

Control group:Anti-infection,pulverization,relieving cough and reducing sputum
Observation group:Anti-infection,pulverization,relieving cough and reducing sputum,Use manna to clear the plague formula

Sponsors

The Forth Affiliated Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the above Western medical diagnostic criteria, are diagnosed with community-acquired pneumonia (pneumonia) and belong to mild to moderate disease, and meet the diagnostic criteria of traditional Chinese medicine for wind-temperature pulmonary fever. (2) Patients aged 18-75 years old, (3) hospitalized for no less than 5 days and laboratory tests Laboratory tests not less than 3 times, (4) Volunteers after detailed understanding of the content of the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those with allergies, allergies to traditional Chinese medicine ingredients; (2) tumors, pregnant or lactating women; (3) Those who are mentally unable to cooperate, suffer from mental illness, have no self-control, and cannot express themselves clearly; (4) Those who are participating in other clinical trials; (5) According to the judgment of the investigator, there will be patients with complications of enrollment or poor compliance that affect the efficacy and safety assessment, such as patients with pneumothorax, lung cancer, active tuberculosis and other serious lung diseases.

Design outcomes

Primary

MeasureTime frame
Malondialdehyde,MDA;Ferrous ions,Fe2+;glutathione,GSH;Interleukin-6,IL-6;tumor necrosis factor-a, TNF-a;

Secondary

MeasureTime frame
White blood cell count(WBC);Lymphocyte percentage(LYMPH%);C-reactive protein(CRP);

Countries

China

Contacts

Public ContactLi Fengsen

The Forth Affiliated Hospital of Xinjiang Medical University(Xinjiang Uygur Autonomous Region Hospital of Tradition Chinese Medicine)

530443341@qq.com+86 139 9998 0996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026